Natasha Pavlova. King, B., Araki, J., Palm, W., & Thompson, C. B. Xin Cai. (2019). Agata (Aggie) Bielska. Li, A. M., Ducker, G. S., Li, Y., Seoane, J. He has been the chief executive of the hospital since 2010. Advance online publication. Education and career. Zhu, J., Berisa, M., Schwörer, S., Qin, W., Cross, J. R., & Thompson, C. B. (2020). Dr. Thompson, 65, received $300,000 in compensation from Merck in 2017, according to company financial filings. MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. https://www.mskcc.org/.../office-president/craig-b-thompson-biography The company was founded by Memorial Sloan Kettering insiders, including a member of the executive board, the chair of the pathology department and the head of a research lab. Craig Thompson, president and CEO of Memorial Sloan Kettering Cancer Center, resigned from two corporate boards of directors—the pharmaceutical company Merck & Co., and Charles River Laboratories International Inc., a company focused on early-stage drug development and … , While most of the details were not announced, the suit was settled with an agreement wherein Agios entered into a licensing agreement with the University of Pennsylvania regarding specific intellectual property. , Patents arising from Thompson’s research describing the co-stimulatory/inhibitory properties of CD28/CTLA-4, in collaboration with Carl June and Jeffrey Bluestone, were licensed for the development of Abatacept (Orencia) for autoimmune diseases and for use in T cell cloning and CAR T cell production. With this in mind, we’ve put in place many new procedures, including a limited visitor policy. Jingwen (Zhou) Araki. Share. Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. Proline biosynthesis is a vent for TGFβ-induced mitochondrial redox stress. This research has helped advance the understanding and deployment of immunotherapy to treat cancer. Just last year, he received $300,000 … Dr. Thompson settled lawsuits several years ago that were filed by Penn and an affiliated research center, which contended that he hid research to start Agios and did not share the earnings with Penn or the research institute. Proline biosynthesis is a vent for TGFβ-induced mitochondrial redox stress. 4", "Symposium to Address Treatment and Prevention of Infectious Inflammatory and Oncogenic Disease - College of Medicine", "Steven C. Beering Award | Office of Faculty Affairs and Professional Development", "Award & PhD Recipients | Memorial Sloan Kettering Cancer Center", "The American Society for Clinical Investigation", https://en.wikipedia.org/w/index.php?title=Craig_B._Thompson&oldid=970253211, Members of the United States National Academy of Sciences, Uniformed Services University of the Health Sciences faculty, Articles with unsourced statements from March 2018, Wikipedia articles with SUDOC identifiers, Wikipedia articles with WORLDCATID identifiers, Creative Commons Attribution-ShareAlike License, Chairman, Scientific Advisory Board of the Damon Runyon/Walter Winchell Cancer Foundation, Chairman, Board of Scientific Counselors of the National Cancer Institute (2001-2003), Chairman, Medical Advisory Board of the Howard Hughes Medical Institute, The American College of Physicians Award for Medical Science (2011), Steven C. Beering Award for Medical Research (2011), Member, National Academy of Sciences (2005), Stanley N. Cohen Biomedical Research Award (2004), ASCI Award from the American Society of Clinical Investigation (2003), Member, National Academy of Medicine (2002), Fellow, American Academy of Arts and Sciences (1999), Member, American Society for Clinical Investigation (1989), Member, Association of American Physicians, This page was last edited on 30 July 2020, at 06:06. More About The Craig Thompson Lab. Schwörer, S., Berisa, M., Violante, S., Qin, W., Zhu, J., Hendrickson, R. C., Cross, J. R., & Thompson, C. B. Craig B. Thompson, chief executive of Memorial Sloan Kettering Cancer Center, will no longer serve on the board of drug maker Merck. Dr. Thompson, 65, received $300,000 in compensation from Merck in 2017, according to company financial filings. He received clinical training in internal medicine at Harvard Medical School and in medical oncology at the Fred Hutchinson Cancer Research Center at the University of Washington.  He published this work alongside Stanley Korsmeyer’s report of the first pro-apoptotic family member, Bax, and together established the three classes of this gene family and defined their pro-apoptotic and anti-apoptotic roles. Thompson became president and chief executive officer of Memorial Sloan Kettering Cancer Center in November 2010. Postdoctoral fellow. He is married to Tullia Lindsten, also a cancer researcher. Share. His contributions demonstrate why it is so important to have leaders from the medical community represented on the board.”. (2020). , Thompson’s recent research has focused on cellular metabolism. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data. Over the past month, articles in The Times and ProPublica have outlined leaders’ ties to for-profit companies, including an exclusive deal the hospital made with an artificial intelligence start-up to license images of 25 million tissue slides. Senior Research Technician . , Thompson’s laboratory undertakes basic research in the fields of cancer biology and immunology. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. A., Xiao, Y., Melemenidis, S., Zhou, Y., Liu, L., Vanharanta, S., Graves, E. E., Rankin, E. B., Curtis, C., Massagué, J., Rabinowitz, J. D., Thompson, C. B., & Ye, J. Dr. Thompson has served on the board of Merck, the maker of the blockbuster cancer drug Keytruda, since 2008. The move followed two tense meetings at the hospital on Monday, spurred by articles by The New York Times and ProPublica, about insider deals among hospital officials and undisclosed industry relationships. Thompson’s expertise, perspective and dedication to patient care have contributed greatly to Merck’s mission.  His work has also led to new insights into how intracellular metabolite levels can contribute to the regulation of gene expression, cellular differentiation and oncogenic transformation. Yap/Taz promote the scavenging of extracellular nutrients through macropinocytosis. “These same colleagues are not interested in moving forward with a vote of no confidence,” Dr. Abu-Rustum said. This data reflects interests that may or may not still exist. King, B., Araki, J., Palm, W., & Thompson, C. B. We're committed to providing you with the very best cancer care, and your safety continues to be a top priority.